🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to be invited to JPM and tell the Arbor story.

Great to get back to JPM

Today we recognize the strength, achievements and contributions of women at Arbor and across the world. For International Women's Day and beyond, let's #EmbraceEquity to build an inclusive world where difference is valued and celebrated. #InternationalWomensDay2023

Today, Arbor announced that our CEO Devyn Smith will deliver welcoming remarks, participate in a panel and give a presentation at Alliance for Regenerative Medicine (ARM)’s Cell & Gene Meeting on the Med later this month. Learn more in our latest press release: arbor.bio/arbor-biotechn… #CGMed23

WelcomeDan!

Excited to participate in the conference.

Excited to participate with such talented leaders

A great step forward in our understanding of genetic diversity

Pleased to have done this podcast with leading minds.

Very excited that Ajim is joining Arbor as our new CFO

Interested in learning more about Arbor Bio and our extensive toolbox of proprietary genomic editors? Look for CEO Devyn Smith, CTO David Cheng, and CFO Ajim Tamboli at these October conferences. #arborbio #biotech

We’re kicking off #CGMesa23 with a big announcement! We’ve elected our 2024 Board of Directors at the conference’s opening. These distinguished individuals will be key to ARM’s leadership of the sector. A big welcome to our new board members: alliancerm.org/press-release/… 1/3

A fun discussion with Tim Hunt

ICYMI: Arbor Bio CEO Devyn Smith recently joined host Jasmeet Sawhney on the Leading Minds Podcast to discuss his trajectory in the field and his view on purposefully contributing to the therapeutic landscape. Tune in to hear more: bit.ly/45b8tos

We’re honored to welcome Nolan to welcome our Board of Directors. His knowledge and experience will be invaluable as we advance our platform technologies and work to bring novel therapies to patients with high unmet need. Learn more: bit.ly/3tZProd

Enjoyed my conversation with PharmaVoice about Arbor.

Arbor CEO Devyn Smith reflects on 2023. What do you most look forward to in 2024? #CRISPR #biotech #GeneEditing

Happy to partner our next gen editing approaches with 4DMT next gen capsids for CNS diseases

Excited to work with Allogene Therapeutics together on next gen cell therapy for autoimmune disease!

Pleased to add some key technology and assets from Serendipity.